Oral heparin Emisphere

Keyphrases

• Heparin 100%
• Elan 26%
• Deep Vein Thrombosis 21%
• Sodium 15%
• Amino 15%
• Oral Formulation 15%
• Decanoate 15%
• Primates 10%
• Canada 10%
• Phase I Trial 10%
• Phase II Study 10%
• Low Molecular Weight Heparin 10%
• Oral Administration 10%
• Hip Surgery 10%
• Oral Delivery 10%
• Potential Treatments 5%
• First Year 5%
• Lipoproteins 5%
• Therapeutic Levels 5%
• Amino Acids 5%
• Serum Levels 5%
• 4-fold 5%
• Delivery System 5%
• Subcutaneous Injection 5%
• Phase II Trial 5%
• Hip Replacement 5%
• Venous Thromboembolic Events 5%
• Financial Support 5%
• Four-phase 5%
• USPTO 5%
• Orally Administered 5%
• Hip Arthroplasty 5%
• Heparinoid 5%
• Inhibitor Concentration 5%
• Carrier System 5%
• Knee Surgery 5%
• Delivery Technologies 5%
• Royalty 5%
• Coagulation Inhibitors 5%
• Carrier Molecules 5%
• Transmembrane Delivery 5%
• PODDS 5%
• Enoxaparin Sodium 5%
• Profit Split 5%
• Blood Clotting Time 5%
• Novel Carriers 5%
• Joint Venture Agreements 5%
• Product Sales 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Heparin 100%
• Deep Vein Thrombosis 21%
• Decanoic Acid 15%
• Phase I Trials 10%
• Low Molecular Weight Heparin 10%
• Malignant Neoplasm 5%
• Thromboembolism 5%
• Amino Acid 5%
• Bioavailability 5%
• Subcutaneous Injection 5%
• Clotting Time 5%
• Enoxaparin 5%
• Tissue Factor Pathway Inhibitor 5%
• Heparinoid 5%